Archive · 29 Aug 2026
US FDA Inspection Finds Three Observations at Apitoria Plant
The US drug regulator inspected a medicine-making factory run by Apitoria Pharma.
The inspection happened from August 24 to August 28.
Inspectors listed three observations, meaning they found issues that may need attention.
Aurobindo Pharma said the issues were procedural.
The company plans to send its response to the regulator on time.
Another company facility, run by AuroPeptides, had one observation during a separate inspection.
Aurobindo has not explained what the specific observations were.
An observation is not automatically a final punishment, because the company can respond and make corrections.
A US FDA inspection at Apitoria Pharma’s Unit-VI facility ended with three observations.
The inspection took place from August 24 to August 28 in Andhra Pradesh’s Anakapalli district.
Aurobindo Pharma described the observations as procedural and said it would respond within the required timeline.
A separate inspection at AuroPeptides’ Telangana facility produced one observation from August 17 to August 21.
Aurobindo Pharma shares closed 0.92% higher at ₹1,652 on Friday.
- Who
- The US Food and Drug Administration inspected facilities operated by Aurobindo Pharma subsidiaries Apitoria Pharma and AuroPeptides.
- What
- The Apitoria Pharma inspection ended with three observations, while the AuroPeptides inspection ended with one.
- When
- Apitoria Pharma was inspected from August 24 to August 28; AuroPeptides was inspected from August 17 to August 21.
- Where
- Apitoria Pharma’s Unit-VI is in E-Bonangi Village, Parawada Mandal, Andhra Pradesh’s Anakapalli district; AuroPeptides’ facility is in Indrakaran Village, Kandi Mandal, Telangana.
- Why
- The articles do not state why the inspections were scheduled.
Company’s Position
Regulatory Interpretation
Meaning of the observations
Company’s Position
Aurobindo Pharma described all three Apitoria observations as procedural in nature.
Regulatory Interpretation
An FDA observation indicates that inspectors identified conditions that may not fully comply with regulatory requirements.
Regulatory consequences
Company’s Position
The company said it remains focused on quality and regulatory compliance and will take corrective steps through its formal response.
Regulatory Interpretation
The observations are not automatically final regulatory action, but the facilities must respond and may need corrective measures.
Details of the findings
Company’s Position
Aurobindo Pharma has not disclosed the specific observations from either inspection.
Regulatory Interpretation
Because the findings were not disclosed, the articles do not establish the precise nature or severity of the issues.
- Apitoria facility
- Unit-VI, operated by wholly owned subsidiary Apitoria Pharma
- Apitoria inspection
- August 24–28
- Apitoria findings
- Three observations
- AuroPeptides inspection
- August 17–21, with one observation
- Combined findings
- Four observations across two subsidiaries within one week
- Company response
- Aurobindo Pharma said it would submit responses within the prescribed timelines
- Share price
- ₹1,652 at Friday’s close, up 0.92%